Validation of psoriasis clinical severity and outcome measures: Searching for a gold standard

Archives of Dermatology

Volumn 147, Issue 1, 2011, Pages 95-98

  Jensen, J Daniel ^a   Fujita, Mayumi ^a   Dellavalle, Robert P ^a,b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Food Science and Human Nutrition   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT;

BODY SURFACE; CLINICAL FEATURE; DISEASE SEVERITY; GOLD STANDARD; HUMAN; LATTICE SYSTEM PSORIASIS GLOBAL ASSESSMENT; NOTE; OUTCOME ASSESSMENT; PATIENT GLOBAL ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS EXACT AREA AND SEVERITY INDEX; PSORIASIS GLOBAL ASSESSMENT; PSORIASIS LOG BASED AREA AND SEVERITY INDEX; PSORIASIS SEVERITY INDEX; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RELIABILITY; SCORING SYSTEM; SELF ADMINISTERED PSORIASIS AREA AND SEVERITY INDEX; SIMPLIFIED PSORIASIS AREA AND SEVERITY INDEX; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDATION STUDY; VALIDITY;

EID: 78751561328     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.242     Document Type: Note

References (22)

1. Marks R, Barton SP, Shuttleworth D, Finlay AY. Assessment of disease progress in psoriasis. Arch Dermatol. 1989;125(2):235-240.
2. Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol. 1991;124(6):565-570.
3. Yune Y-M, Park SY, Oh HS, et al. Objective assessment of involved surface area in patients with psoriasis. Skin Res Technol. 2003;9(4):339-342.
4. Tiling-Grosse S, Rees J. Assessment of area of involvement in skin disease: a study using schematic figure outlines. Br J Dermatol. 1993;128(1):69-74.
5. Savolainen L, Kontinen J, Alatalo E, Röning J, Oikarinen A. Comparison of actual psoriasis surface area and the psoriasis area and severity index by the human eye and machine vision methods in following the treatment of psoriasis. Acta Derm Venereol. 1998;78(6):466-467. (Pubitemid 28505966)
6. Savolainen L, Kontinen J, Röning J, Oikarinen A. Application of machine vision to assess involved surface in patients with psoriasis. Br J Dermatol. 1997;137(3):395-400. (Pubitemid 27421567)
7. Kreft S, Kreft M, Resman A, Marko P, Kreft KZ. Computer-aided measurement of psoriatic lesion area in a multicenter clinical trial - comparison to physician's estimations. J Dermatol Sci. 2006;44(1):21-27. (Pubitemid 44321971)
8. Ormerod AD, Dwyer CM, Weller R, Cox DH, Price R. A comparison of subjective and objective measures of reduction of psoriasis with the use of ultrasound, reflectance colorimetry, computerized video image analysis, and nitric oxide production. J Am Acad Dermatol. 1997;37(1):51-57. (Pubitemid 27287693)
9. Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. J Am Acad Dermatol. 2004;51(4):563-569.
10. Gottlieb AB, Chaudhari U, Baker DG, Perate M, Dooley LT. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol. 2003;2(3):260-266.
11. Rakkhit T, Panko JM, Christensen TE, et al. Plaque thickness and morphology in psoriasis vulgaris associated with therapeutic response. Br J Dermatol. 2009;160(5):1083-1089.
12. Serup J, Agner T. Colorimetric quantification of erythema - a comparison of two colorimeters (Lange Micro Color and Minolta Chroma Meter CR-200) with a clinical scoring scheme and laser-Doppler flowmetry. Clin Exp Dermatol. 1990;15(4):267-272.
13. Lahti A, Kopola H, Harila A, Myllylä R, Hannuksela M. Assessment of skin erythema by eye, laser Doppler flowmeter, spectroradiometer, two-channel erythema meter and Minolta chroma meter. Arch Dermatol Res. 1993;285(5):278-282.
14. Harari M, Shani J, Hristakieva E, Stanimirovic A, Seidl W, Burdo A. Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead-Sea. Int J Dermatol. 2000;39(12):913-918.
15. Jacobson CC, Kimball AB. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol. 2004;151(2):381-387.
16. Berth-Jones J, Grotzinger K, Rainville C, et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. Br J Dermatol. 2006;155(4):707-713.
17. Kirby B, Fortune DG, Bhushan M, Chalmers RJ, Griffiths CE. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol. 2000;142(4):728-732.
18. Sampogna F, Sera F, Abeni D; IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Investigators. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol. 2004;122(3):602-607.
19. Feldman SR, Fleischer AB Jr, Reboussin DM, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol. 1996;106(1):183-186.
20. Szepietowski JC, Sikora M, Pacholek T, et al. Clinical evaluation of the self-administered psoriasis area and severity index (SAPASI). Acta Dermatovenerol Alp Panonica Adriat. 2001;10(3):79-83.
21. Sampogna F, Sera F, Mazzotti E, Pasquini P, Picardi A, Abeni D; IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Study Group. Performance of the self-administered psoriasis area and severity index in evaluating clinical and sociodemographic subgroups of patients with psoriasis. Arch Dermatol. 2003;139(3):353-358.
22. Louden BA, Pearce DJ, Lang W, Feldman SR. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J. 2004;10(2):7.